QTRX
Quanterix Corp.
NASDAQ · Healthcare · Medical - Devices · US
$3.07
−1.60%Sep 17, 2026, 01:00 UTC
Quanterix Corporation granted inducement equity awards to newly appointed Chief Commercial Officer James Gute and two other employees in connection with the start of their employment.
Source:Aug 16, 2026, 18:02 UTC
Quanterix is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences.
Source:Aug 10, 2026, 12:01 UTC
Quanterix Corporation appointed Jim Gute as Chief Commercial Officer on August 10, 2026.
Source:Aug 10, 2026, 12:00 UTC
Quanterix Corporation announced its financial results for the second quarter ended June 30, 2026, reporting revenue below expectations due to execution challenges and market softness, while preserving cash better than planned.
Jul 14, 2026, 20:29 UTC
Anthem Blue Cross and Blue Shield established commercial coverage for Quanterix's LucentAD Complete blood test for Alzheimer's disease.
Source:Jun 9, 2026, 00:00 UTC
Quanterix Corp appointed Jason Faessler as Chief Financial Officer and Treasurer, effective June 22, 2026.
Source: